These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12219739)

  • 21. [Prevalence of primary drug resistance in M. tuberculosis in four administrative areas of the North-Western Federal District of the Russian Federation].
    Baranov AA; Mar'iandyshev AO; Nizovtseva NI; Oparina EN; Presnova SE; Gvozdovskaia LA; Markelov IuM; Trekin IA; Tungusova OS; Mannsoker T
    Probl Tuberk Bolezn Legk; 2006; (12):9-12. PubMed ID: 17300065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China.
    Chen L; Gan X; Li N; Wang J; Li K; Zhang H
    J Antimicrob Chemother; 2010 Jun; 65(6):1299-301. PubMed ID: 20356906
    [No Abstract]   [Full Text] [Related]  

  • 23. Genetic diversity of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Poland and assessed by spoligotyping.
    Augustynowicz-Kopec E; Jagielski T; Zwolska Z
    J Clin Microbiol; 2008 Dec; 46(12):4041-4. PubMed ID: 18832130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tuberculosis caused by Mycobacterium bovis, a re-emerging infection?].
    Pérez-Barragán E; Manjarrez-Tellez B
    Rev Med Inst Mex Seguro Soc; 2017; 55(5):635-640. PubMed ID: 29193947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis in Saudi Arabia: the journey across time.
    Al-Hajoj S; Varghese B
    J Infect Dev Ctries; 2015 Mar; 9(3):222-31. PubMed ID: 25771458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 27. Montpellier Infectious Diseases - Pôle Rabelais (MID) 3rd annual meeting (2014).
    Besteiro S; Blanc-Potard A; Bonazzi M; Briant L; Chazal N; Cornillot E; Lentini G; Matkovic R; Sanosyan A; Tuaillon E; Van de Perre P
    Infect Genet Evol; 2015 Jun; 32():161-4. PubMed ID: 25791932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimising moxifloxacin resistance with tuberculosis.
    Drlica K; Zhao X; Kreiswirth B
    Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Zhang YJ; Li XJ; Mi KX
    Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
    Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
    Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 32. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis.
    Eilertson B; Maruri F; Blackman A; Herrera M; Sterling TR
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1276-7. PubMed ID: 27510259
    [No Abstract]   [Full Text] [Related]  

  • 33. [Infectious and parasitic diseases in Brazil: a decade of transition].
    Paes NA; Silva LA
    Rev Panam Salud Publica; 1999 Aug; 6(2):99-109. PubMed ID: 10574011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging and re-emerging infectious diseases: a continuous challenge for Europe.
    Quaglio G; Demotes-Mainard J; Loddenkemper R
    Eur Respir J; 2012 Dec; 40(6):1312-4. PubMed ID: 23204016
    [No Abstract]   [Full Text] [Related]  

  • 35. EDITORIAL: New Avenues in Controlling Infectious Diseases.
    Rathi B; Latha N; Faletrov Y; Bhargava P; Shkumatov V
    Curr Top Med Chem; 2017; 17(19):2113. PubMed ID: 28664823
    [No Abstract]   [Full Text] [Related]  

  • 36. Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.
    Mustazzolu A; Iacobino A; Giannoni F; Piersimoni C; ; Fattorini L
    J Clin Microbiol; 2017 Dec; 55(12):3552-3553. PubMed ID: 28904184
    [No Abstract]   [Full Text] [Related]  

  • 37. [Signal transduction and drug resistance in Mycobacterium tuberculosis--A review].
    Wang S; Feng Y; Zhang Z
    Wei Sheng Wu Xue Bao; 2015 Aug; 55(8):971-6. PubMed ID: 26665593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sensitivity of Mycobacterium tuberculosis in our environment].
    Unzaga MJ; Sota M; Melero P; Berdonces P; Ezpeleta C; Cisterna R
    Enferm Infecc Microbiol Clin; 1996; 14(6):399-400. PubMed ID: 8756225
    [No Abstract]   [Full Text] [Related]  

  • 39. [Drug-resistance in Mycobacterium tuberculosis in Castilla y León, Spain, 2001-2005: third collaborative study].
    Alberte-Castiñeiras A; Campos-Bueno A; López-Urrutia L; Alvarez-Alonso E; Megías G; Ojeda-Fernández E; López-Medrano R; Iglesias-García J; García-Carbajosa S; Pérez-Pascual P
    Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):706-9. PubMed ID: 20627375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment on: isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Köser CU; Summers DK; Archer JA
    J Antimicrob Chemother; 2011 Mar; 66(3):686-7; author reply 687. PubMed ID: 21177677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.